Synlogic Therapeutics

Business model

Engineered synthetic-biotic bacterial therapies designed to treat rare metabolic diseases.

In brief

Pioneered a genuinely novel therapeutic approach — engineering living bacteria to treat metabolic diseases — with its lead program targeting phenylketonuria (PKU), a rare inherited disorder. When its drug candidate failed to meet its primary endpoint in a pivotal Phase 3 trial in…

See the What Happened tab for the full account.